Extended Adjuvant Therapy Beneficial for Some Women with Breast Cancer
June 22, 2016 by NCI Staff
Extended Adjuvant Therapy for Breast Cancer - National Cancer Institute
Results from a recent clinical trial showed that extending adjuvant therapy with an aromatase inhibitor to 10 years after initial treatment can have important benefits for postmenopausal women with early-stage hormone receptor (HR)–positive breast cancer. The longer treatment improved 5-year disease-free survival and decreased the women’s risk of developing cancer in the opposite breast, called contralateral breast cancer.
The findings were published in the New England Journal of Medicine on June 5 and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The trial is the first to show that extending adjuvant therapy with an aromatase inhibitor beyond 5 years in this patient group can improve outcomes, explained the trial’s lead investigator, Paul Goss, M.D., Ph.D., of Massachusetts General Hospital in Boston. There is no evidence yet that the longer duration of therapy improves overall survival, but in a press briefing at the ASCO meeting Dr. Goss called the reduced risk of contralateral breast cancer a “major benefit.”
Tailoring treatment to individual patients will be important, stressed Jo Anne Zujewski, M.D., of NCI’s Division of Cancer Treatment and Diagnosis. In particular, Dr. Zujewski said, clinicians need to talk with their patients about the risks of side effects with aromatase inhibitors, namely bone-related effects such as fractures, and appropriately manage them in women taking these drugs.
Building on Earlier Trial Findings
Tamoxifen (Nolvadex®), which blocks the activity of the hormone estrogen, has been the drug of choice for preventing breast cancer recurrence since the 1980s and is still used by many clinicians, often in combination, or sequentially, with aromatase inhibitors.
Aromatase inhibitors block aromatase, an enzyme that the body uses to make estrogen.These drugs are used primarily in postmenopausal women, whose ovaries have stopped making estrogen. Postmenopausal women whose breast tumors rely on hormones to fuel their growth have been found to benefit the most from aromatase inhibitor therapy.
In a previous clinical trial, Dr. Goss and his colleagues showed that in women with HR-positive breast cancer who had already undergone 5 years of tamoxifen treatment, an additional 5 years of treatment with the aromatase inhibitor letrozole (Femara®) improved survival outcomes. The trial, called MA.17, also showed that extended letrozole therapy reduced the risk of developing contralateral breast cancer.
However, even with successful initial treatment, women with HR-positive early-stage breast cancer continue to have a risk of their disease returning. Some women can have recurrences even two decades after their initial treatment, Dr. Goss said.
10 Years versus 5 Years of Adjuvant Therapy
So in this new trial, named MA.17R, the researchers wanted to see whether extending letrozole therapy for an additional 5 years—for a total of 10 years of adjuvant treatment—could further reduce recurrence risk. The trial enrolled nearly 2,000 women who had already received 4.5 to 6 years of adjuvant aromatase inhibitor therapy, many of whom were in the MA.17 trial. Within 2 years after completing treatment with an aromatase inhibitor, the women were randomly assigned to receive letrozole or a placebo daily for another 5 years.
After a median follow up of 6.3 years, the women who received letrozole had higher rates of 5-year disease-free survival (95% versus 91%) and lower annual incidence rates of contralateral breast cancer (0.21% versus 0.49%) than the women who received placebo. The 5-year overall survival rate was essentially the same in the two groups: 93% for those who took letrozole, and 94% for those who took placebo.
Quality-of-life measures were also similar for both groups of women. However, women who took letrozole had more bone pain, bone fractures, and newly diagnosed osteoporosis than women who took placebo. Although women in the trial generally fared well in terms of side effects, Dr. Goss stressed that the women in the trial were a highly selected group—those who had already been able to take aromatase inhibitors for 5 years without any major problems.
This is a group of women “who can tolerate the drug, whose quality of life is unchanged and … who [have] no particular toxicities” to aromatase inhibitor therapy, noted Dr. Goss.
For women who are at high risk of recurrence, said Dr. Zujewski, these findings indicate a greater chance that extended aromatase inhibitor therapy may reduce chances of a recurrence. Conversely, if a patient is at low risk of recurrence, lengthening treatment will likely be of little benefit. “You cannot cure a patient twice,” she said.
Dr. Zujewski said that she considers bone density measures when trying to decide whether to recommend tamoxifen, which protects women’s bones after menopause, or an aromatase inhibitor, which can harm bone.
“For patients who use aromatase inhibitors for an extended period of time, I recommend abisphosphonate for bone protection—and studies of bisphosphonates suggest that this may help decrease the risk of metastatic disease as well.
“Monitoring bone health and using bone protecting agents when appropriate in these patients is really important,” said Dr. Zujewski. “In this trial, only about half of the women who had fractures used bisphosphonates. As clinicians, we need to do a better job of protecting the bones of women we consider for extended adjuvant therapy.”
Recent Press Releases
- Newly launched Genomic Data Commons to facilitate data and clinical information sharingJune 6, 2016The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data between researchers, launched today with a visit from Vice President Joe Biden to the operations center at the University of Chicago.
- NIH study visualizes proteins involved in cancer cell metabolismMay 26, 2016Scientists using cryo-electron microscopy have broken through a technological barrier in visualizing proteins with an approach that may have an impact on drug discovery and development, capturing images of an enzyme found in cells at a resolution of 1.8 angstroms.
- Increased Physical Activity Associated with Lower Risk of 13 Types of CancerMay 16, 2016A new study of the relationship between physical activity and cancer has shown that greater levels of leisure-time physical activity were associated with a lower risk of developing 13 different types of cancer; the risk of developing seven cancer types was 20 percent lower among the most active participants as compared with the least active participants.
- Analysis of rare endocrine cancer reveals novel genetic alterationsMay 9, 2016A molecular characterization of adrenocortical carcinoma, a rare cancer of the adrenal cortex, analyzed 91 cases for alterations in the tumor genomes and identified several novel genetic mutations as likely mechanisms driving the disease as well as whole genome doubling as a probable driver of the disease.
- Elevated bladder cancer risk in New England and arsenic in drinking water from private wellsMay 2, 2016A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years.
- NCI opens online platform to submit ideas about research for Cancer MoonshotApril 18, 2016NCI has launched an online platform to enable the research community and the public to submit ideas on the National Cancer Moonshot efforts.
- Blue Ribbon Panel announced to help guide Vice President Biden’s National Cancer Moonshot InitiativeApril 4, 2016The Blue Ribbon Panel, a working group of the National Cancer Advisory Board, will recommend how best to advance the themes of the National Cancer Moonshot Initiative. Panel members represent a spectrum of scientific areas, cancer advocacy groups, and pharmaceutical and biotechnology companies.
- Annual Report to the Nation: Cancer Death Rates Continue to Decline; Increase in Liver Cancer Deaths Cause For ConcernMarch 9, 2016The Report to the Nation on the Status of Cancer (1975-2012) shows that death rates continued to decline for all cancers combined, as well as for most cancer sites for men and women, and also for children.
- New study using cryo-electron microscopy shows how potential drugs could inhibit cancerJanuary 28, 2016An imaging technique called cryo-electron microscopy views, in atomic detail, the binding of a potential drug to a protein in cancer cells.
- TCGA findings on papillary renal cell carcinoma and prostate cancerNovember 5, 2015Researchers with The Cancer Genome Atlas (TCGA) report new findings on papillary renal cell carcinoma and prostate cancer.
No hay comentarios:
Publicar un comentario